Apricus Biosciences Company Profile

11975 El Camino Real

San Diego CA 92130



Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company’s marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV, Neopharm Scientific Limited, Elis Pharmaceuticals Limited, and Global Harvest Pharmaceutical Corporation. It also develops second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and Fispemifene, a tissue-specific selective estrogen receptor modulator that is in Phase IIb clinical trial to treat secondary hypogonadism, lower urinary tract symptoms, and chronic prostatitis in men. In addition, the company plans to initiate a Phase IIb trial for RayVa to treat Raynaud’s phenomenon associated with scleroderma; and develops Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. It operates in Latin America, Europe, and internationally. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Top Fintech Company featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE